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Abstract This paper reviews some computational aspects of Boron Neutron Capture Therapy (BNCT) with the 
emphasis on the BNCT treatment planning system. An example of a computational dosimetry system developed in 
Japan is discussed, particularly, the need of such system for BNCT which uses epithermal neutron beams for non-
craniotomy brain tumors as well as head-&-neck cancers. An example of BNCT dose calculation method is also 
presented. 
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1. INTRODUCTION 
 BNCT is a type of radiation therapy for 
obstinate cancers such as malignant brain 
tumors and melanoma. The physical 
principle of BNCT was presented in 1936 
and its medical application for malignant 
brain tumors had been conducted (Farr 
1954). In the BNCT procedure, doctors 
inject a boron compound that builds up 
selectively in the cancer cells of a patient at 
first, and subsequently the affected region of 
the patient is irradiated by a neutron beam 
from a reactor core. Alpha particles and 
lithium atoms, which are generated by 
interactions between neutrons and boron-10 
atoms in the cells, destroy cancer cells 
selectively. In the last decade, clinical trials 
of BNCT with epithermal neutron beams 
have been performed around the world. By 
using the epithermal neutron beams, the 
therapeutic range is expanded to deeper 
regions in the brain more than using thermal 
neutron beams. 
 Traditionally, the neutron source for 
BNCT is generated from a nuclear reactor 
where neutron beams are used directly or via 
a fission converter. However, nuclear 
reactor-based BNCT apparatus requires 
complicated maintenance, handling, and 
subjection to nuclear reactor regulations 
hence it is rather not suitable as a medical 
device to be installed in a hospital. 
Particularly in Japan, accelerator-based 
BNCT apparatus, recently, has been 
considered more feasible since it is safer, 
simpler and more compact to be installed in 
a hospital. 
 Historically, clinical trials for BNCT in 
Japan had been performed using thermal 
neutron beams at several research reactors: 
Japan Research Reactor No.2 (JRR-2), 
Musashi Institute of Technology Reactor 
(MuITR) and Kyoto University Research 
Reactor (KUR) (Nakagawa and Hatanaka 
1997). To deliver thermal neutrons to depth 
in the brain, the BNCT procedure at that time 
had included craniotomy such as skin flap 
reopening and bone removal. 
 Before the Fukushima Dai-Ichi Nuclear 
Power Plant accident (March 2011) where all 
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research reactors in Japan were in operation, 
the clinical trials for BNCT were performed 
using mainly epithermal neutron beams at 
JRR-4 and at KUR.   The BNCT clinical trial 
at JRR-4 has started since 1999 (Yamamoto 
et al. 2004). First, the BNCT trials in JRR-4, 
Intra-Operative BNCT (IOBNCT) including 
the craniotomy were performed with thermal 
neutron beams. Based on further 
developments described below and the 
experiences obtained from the IOBNCT, 
since 2003 clinical trials using epithermal 
neutron beams have been performed at JRR-
4 (Matsumura et al. 2004). 
 At present (2017), research reactors in 
Japan must submit new licenses for 
restarting the reactors after fulfilling the new 
safety standards and regulations imposed 
after the accident. JRR-4 has submitted a 
decommissioning plan at the end of 2015 and 
cannot be used for BNCT any longer. At 
present, the KUR is applying for a license to 
restart its reactor and hopefully in near future 
the reactor can be utilized again for BNCT. 
We can conclude that the role of accelerators 
for BNCT has become more important in 
Japan. At present, accelerator-based BNCT 
facilities were installed at Kyoto University 
Research Reactor Institute (Kyoto) and at the 
Southern Tohoku General Hospital of the 
Southern Tohoku Research Institute for 
Neuroscience (Koriyama City in Fukushima 
Prefecture). Another accelerator-based 
BNCT facility is being constructed in the 
Ibaraki Neutron Research Center 
(Tokaimura, Ibaraki Prefecture). 
 The computational aspects of BNCT 
apparatus or system cover the following: (1) 
Neutron source (fission reactor, fission 
converter, accelerator, target, shielding etc.), 
(2) Neutron beam transport (filter, 
collimator, shutter, shielding etc.) and (3) 
Treatment planning system. In this paper, a 
review on the computational aspects of 
BNCT treatment planning system is given by 
taking an example of a system developed in 
Japan. 
  
2. JAEA COMPUTATIONAL DOSI-
METRY SYSTEM 
 Japan Atomic Energy Agency (JAEA, 
former name JAERI) Computational 
Dosimetry System (JCDS) was developed 
by JAEA (Kumada et al. 2005) to carry out 
the clinical trials based on an optimum 
treatment plan determined by accurate dose 
calculations. The BNCT clinical trial based 
on the treatment planning with JCDS was 
started in 2003. JCDS was employed to 
every BNCT procedure in JRR-4. 
 Clinical trial for head-&-neck cancer was 
also performed in JRR-4 since 2005 (Morita 
et al. 2006). In the treatment planning for the 
head-&-neck cancer BNCT, the geometry 
involved in the dose calculations is more 
complex since it includes oral, nasal cavity 
and lung. Therefore, there is a strong need to 
develop a precise calculation model in order 
to determine an optimum treatment plan. 
 Under these development efforts, JCDS is 
being improved to deal with the treatment 
planning for head-&-neck cancer as well as 
malignant brain tumor. 
 
2.1. System Configuration of JCDS 
 In neutron irradiation in the BNCT 
procedure, to evaluate properly the 
prescribed doses given to a patient, JCDS 
has been developed by JAEA. Fig. 1 shows 
the scheme of dosimetry computation 
process using JCDS. JCDS creates a 
patient’s 3D model based on patient’s 
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medical images such as CT (Computer 
Tomography) and MRI (Magnetic 
Resonance Imaging). By using the CT image 
data, compositions of the human body are 
automatically differentiated from bone, soft 
tissues and air according to CT values (See 
Chapter 3 for detail explanation). On the 
other hand, the MRI image data are used for 
defining several regions such as tumor 
region, target region and critical organs 
called “Region Of Interest (ROI)” as 
important information for the dosimetry. 
 
Fig. 1. Process of computational dosimetry with 
JCDS 
 By superimposing the MRI images onto 
the CT images, a detailed 3D model 
including the compositions information and 
the ROI information is created. To 
effectively compute distributions of several 
dose components and neutron fluxes in the 
body, JCDS converts the detailed 3D model 
into a voxel calculation model. The voxel 
model consists of 10×10×10 mm3 voxel 
(10mm voxel) cells that contain proper 
material data in each voxel cell (See Chapter 
3 for detail explanation). The distributions of 
the dose components and fluxes in the voxel 
model are determined by MCNP-4 which is 
a general Monte-Carlo neutron and photon 
particle transport code (Briesmeister 2000). 
Finally, JCDS evaluates the detailed 
distributions of the dose components in the 
original detailed 3D model by interpolating 
the voxel calculation results. The 
development of JCDS enables determination 
of the optimum conditions for irradiation of 
BNCT. 
2.2. Improvement of JCDS 
 JCDS in the initial version employed a 
voxel calculation method by dividing 
geometry into 10mm voxel cells in order to 
calculate the dose distributions effectively. 
In the second version of JCDS, it became 
possible to create a multi-voxel model 
combined with 5×5×5 mm3 voxel cells 
(Kumada et al. 2004a). Each dose value in 
each voxel cell was determined by the “cell 
tally” function in MCNP-4. The calculation 
accuracy of JCDS was verified by 
comparing with measurements obtained 
from cylindrical water phantom experiments 
(Kumada et al. 2004b). Verification results 
proved that JCDS had sufficient 
performance for dose evaluation in BNCT, 
except for the evaluation near the phantom's 
surface. The results also indicated that JCDS 
produced discrepancy at boundary regions 
between air and soft tissues. 
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Fig. 2. Voxel model consisting of 2mm voxel cells 
 In the dose evaluations for head-&-neck 
cancer BNCT, skin, oral mucosa and nasal 
mucosa are regarded as important regions 
which shall be treated cautiously to limit the 
dose of those regions, and therefore they 
should be evaluated with higher accuracy to 
perform dose evaluation with higher 
accuracies, JCDS was improved to include 
the capability of creating a detailed voxel 
model consisting of 1×1×1 mm3 voxel cells 
or 2×2×2 mm3 voxel cells (2 mm voxel).  
Fig. 2 shows a patient’s voxel model 
consisting of the 2 mm voxel cells. JCDS 
was also modified such that mesh tally 
function installed in MCNP-5 can be applied 
to dose evaluations. The mesh tally function 
allows effective computing of detail dose 
distributions. 
 Recently, along with the adoption of 
accelerator as the neutron source for BNCT, 
the JCDS solver, MCNP-5, was replaced by 
PHITS (Particle and Heavy Ion Transport 
Code System) (Sato et al. 2013). By using 
PHITS, the treatment planning system can 
also be used for proton therapy, heavy ion 
therapy, that is, combined modality therapy 
beside accelerator-based BNCT. 
2.3. Verification of JCDS 
 To demonstrate the calculation 
performance of the modified JCDS applying 
a detailed voxel calculation, verifications 
were performed. Fig.3-(a) shows a 
phantom’s voxel model consisted of 10mm 
voxel cells, while Fig. 3-(b) shows the one 
for 2 mm voxel cells. In the verification, as 
for the irradiation beam to the phantom, 
epithermal neutron beam mode which will 
be applied to BNCT clinical trials was 
selected. The beam outlet was shaped to 
form a circular geometry with 10 cm 
diameter. Distributions of thermal neutron 
flux in the phantom were determined with 
the mesh tally and the cell tally respectively, 
and finally the calculation results were 
compared with the experimental values. 
 In the calculations with the 10 mm voxel 
model, 3D distributions in the phantom were 
determined by using both cell tally and mesh 
tally. In the benchmark for the 2 mm voxel 
model, only mesh tally calculation was 
performed. Particle histories for each 
condition are 800 million. 
 Accuracy of mesh tally calculation was 
confirmed by comparing with results of cell 
tally calculation which has been already 
applied to clinical trials. With cell tally 
values, the mesh tally values at each 
corresponding point in the phantom were in 
good agreement within the error of less than 
3%. The discrepancy is within statistical 
uncertainty of the Monte-Carlo calculations. 
The results demonstrated that dose 
evaluation with MCNP-5 allows to switch 
from cell tally to mesh tally. 
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Fig. 3. Voxel model for the cylindrical water 
phantom 
 Influences of miniaturization of voxel 
model were confirmed continuously. 
Thermal neutron flux profiles on beam’s 
central axis in the phantom for experimental 
data, calculated values for 10 mm and 2 mm 
voxel models. Both calculated values were 
obtained by mesh tally. The detailed 
distributions on the axis for both calculation 
profiles were determined by interpolating 
the calculated values of each voxel cell using 
JCDS function. Comparing with the 
experimental values showed that both 
calculations in phantom deeper than 1 cm 
produced errors of less than 5%. The value 
of the 2 mm voxel model on the phantom's 
surface was also in agreement with the 
experimental value within experimental 
error. However, the value of the 10 mm 
voxel model was overestimated by 
approximately 40%. These results proved 
that the miniaturization of the voxel model 
enhanced the accuracy of the dose 
calculation in the BNCT’s dosimetry. The 
results demonstrated that detailed voxel 
model with 2 mm voxel cells combined with 
mesh tally option can be employed to 
treatment planning in actual BNCT trials. 
 The verification results show that 
calculation methodology adopting the 2 mm 
voxel model is practical and efficient. Based 
on the results, for the treatment planning in 
BNCT procedure, dose calculation using 2 
mm voxel model with mesh tally has been 
applied. The same accuracy was achieved by 
the PHITS code and practically now PHITS 
code has become the solver module for 
BNCT treatment planning systems in Japan. 
 
3. DETAIL COMPUTATIONAL 
ASPECTS 
 In this chapter, a more detail explanation 
on some computational aspects of JCDS is 
given. 
 In JCDS, the preferred patient’s image data 
format is DICOM. DICOM stands for 
Digital Imaging and Communications in 
Medicine, and it is a standard format for 
handling, storing, printing, and transmitting 
information in medical imaging. It includes 
a file format definition and a network 
communications protocol. 
 The tissue material composition definition 
adopted in JCDS is based on ICRU-46 
(White 1992) which includes H, C, N, O, Na, 
P, S, Cl, K, Mg and Ca elements. 
 In JCDS, a user can use built-in materials 
(1) soft tissue, (2) tumor, (3) bone, (4) air, 
and (5) lithium helmet. Lithium helmet is 
needed especially for brain tumor BNCT 
protocol. 
 Based on the patient’s CT data the voxel 
based material data is determined as 
illustrated From the CT data, the type of 
material is determined automatically by 
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using prescribed ranges of mass density as 
shown in the upper part of the figure. The air 
containing pixel can be easily detected since 
its mass density is very different from human 
parts. The next denser material is the soft 
tissue (which may be normal tissue or tumor 
tissue). The soft tissue has a certain range of 
mass density which is used to detect the soft 
tissue region. The densest material is bone, 
and similarly it has a certain range of mass 
density. 
 Since a voxel dimension is usually larger 
than a pixel dimension, a voxel may contain 
more than one type of material as shown in 
the lower part of the figure. In JCDS, a 
limited number of available material mixing 
sets (amongst types of materials) can be used 
to define the final voxel composition which 
will be used by the MCNP-5 or PHITS code.  
 
Fig. 4. Voxel-based material data for MCNP/PHITS 
code calculation 
 In this example, a voxel is composed of 
65% volume of soft tissue and the rest is 
bone (based on the CT data). There are six 
sets of material mixing available and the 
nearest one is set number 4 (60%:40% of soft 
tissue and bone volume fractions, 
respectively) and it is automatically assigned 
to the voxel. 
4. COMPUTATIONAL BNCT DOSE 
 The BNCT dose computation conducted in 
a treatment planning system is an important 
part of the system. Unfortunately, there is 
still no global standard procedure for BNCT 
dose computation, that is, each institution 
has its own procedure which is not 
necessarily identical with other institution. 
 Here, an example of BNCT dose 
calculation procedure is given (JSNCT 
2011). The absorbed dose components of 
BNCT are illustrated in Fig. 5, namely, (1) 
boron-10 dose from 10B(n,α)7Li reaction 
(DB), (2) hydrogen dose from 
1H(n,n’)p 
reaction (DH), (3) nitrogen dose from 
14N(n,p)14C reaction (DN) and gamma dose 
(DG). The gamma dose can be further 
divided into two components, the one from 
the primary beam source and the one 
(secondary) from 1H(n,𝛾)2H reaction. 
 
Fig. 5. BNCT dose components 
 As shown in Fig. 5, during BNCT we 
expect that the tumor dose should be much 
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higher than the one of the normal tissue dose. 
In other words, the treatment planning 
system should obtain the maximum dose 
advantage shown in the figure. 
 Fig. 6 shows the BNCT equivalent dose 
(Gy-Eq) equation and the recommended 
weighting factors. The boron-10 dose 
depends on the compound biological effect 
(CBE) for tumor, normal and skin tissues. 
Furthermore, the CBE depends also on the 
boron delivery agent (drug) type. At present, 
there are two choices of delivery agent, 
namely, sodium borocaptate (BSH) and 
boronophenyl-alanine (BPA). The other 
doses components use relative biological 
effectiveness (RBE) which does not depend 
on the delivering agent. 
 
Fig. 6. BNCT absorbed dose equivalent calculation 
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